Rana Tuna DOĞRUL, Cagatay ÇAVUŞOĞLU, Gozde Sengul AYÇİÇEK, Cemile ÖZSÜREKÇİ, Hatice ÇALIŞKAN, Hacer DOĞAN VARAN, Zeliha GÜNNÜR DİKMEN, Mustafa CANKURTARAN, Burcu Balam DOĞU

Can Syndecan-1 Be Used As A Biomarker In Alzheimer’s Disease?

Background: Syndecan-1 (SDC-1) is a member of the syndecan family, which includes heparan sulfate proteoglycans. SDC-1 is important for cell-cell and cell-matrix interactions. The aim of this study is to examine the relationship between serum SDC-1 levels and mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Methods: Eighty-two patients aged 65 years and over were included in the study. The Mini-Mental State Examination (MMSE) was used to evaluate the cognitive functions of the patients. Comprehensive geriatric assessment components were administered to the patients. Serum SDC- 1 levels were measured with an enzyme-linked immunosorbent assay kit. Results: When patients were grouped as control, MCI and AD, significant decreases were observed in Katz daily living activity (p

PDF

___

[1] Vagnucci Jr, A.H. and W.W. Li, Alzheimer’s disease and angiogenesis. The Lancet, 2003. 361(9357): p. 605-608.
[2] Morris, G.P., I.A. Clark, and B. Vissel, Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer’s disease. Acta neuropathologica communications, 2014. 2(1): p. 1-21.
[3] Liu, C.-C., et al., Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer’s disease. Science translational medicine, 2016. 8(332): p. 332ra44-332ra44.
[4] Bruinsma, I.B., et al., Sulfation of heparan sulfate associated with amyloid-β plaques in patients with Alzheimer’s disease. Acta neuropathologica, 2010. 119(2): p. 211-220.
[5] Nguyen, K. and D.L. Rabenstein, Interaction of the heparinbinding consensus sequence of β-amyloid peptides with heparin and heparin-derived oligosaccharides. The Journal of Physical Chemistry B, 2016. 120(9): p. 2187- 2197.
[6] Palaiologou, M., I. Delladetsima, and D. Tiniakos, CD138 (syndecan-1) expression in health and disease. 2014.
[7] Petersen, R.C., et al., Mild cognitive impairment: clinical characterization and outcome. Archives of neurology, 1999. 56(3): p. 303-308.
[8] McKhann, G., et al., Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 1984. 34(7): p. 939-939.
[9] American Psychiatric Association, A. and A.P. Association, Diagnostic and statistical manual of mental disorders: DSM-5. 2013, Washington, DC: American psychiatric association.
[10] Reisberg, B., Functional assessment staging (FAST). Psychopharmacol Bull, 1988. 24: p. 653-659.
[11] Katz, S., et al., Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. Jama, 1963. 185(12): p. 914-919.
[12] Lawton, M.P. and E.M. Brody, Assessment of older people: self-maintaining and instrumental activities of daily living. The gerontologist, 1969. 9(3_Part_1): p. 179-186.
[13] Yesavage, J.A., Geriatric depression scale. Psychopharmacol Bull, 1988. 24(4): p. 709-711.
[14] Rubenstein, L.Z., et al., Screening for undernutrition in geriatric practice: developing the short-form mininutritional assessment (MNA-SF). The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2001. 56(6): p. M366-M372.
[15] Folstein, M.F., S.E. Folstein, and P.R. McHugh, “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. Journal of psychiatric research, 1975. 12(3): p. 189-198.
[16] Stahelin, H.B., A.U. Monsch, and R. Spiegel, Early diagnosis of dementia via a two-step screening and diagnostic procedure. International Psychogeriatrics, 1997. 9(1): p. 123-130.
[17] Letoha, T., et al., Contribution of syndecans to cellular internalization and fibrillation of amyloid-β (1–42). Scientific reports, 2019. 9(1): p. 1-17.
[18] Mahley, R.W., Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. Journal of molecular medicine, 2016. 94(7): p. 739-746.
[19] Carter, D.B., The interaction of amyloid-β with ApoE. Alzheimer’s Disease, 2005: p. 255-272.
[20] Hudák, A., et al., The Interplay of Apoes with Syndecans in Influencing Key Cellular Events of Amyloid Pathology. International journal of molecular sciences, 2021. 22(13): p. 7070.
[21] O’Bryant, S.E., et al., Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimer’s & Dementia, 2015. 11(5): p. 549-560.
[22] Andreasson, U., K. Blennow, and H. Zetterberg, Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2016. 3: p. 98-102.
[23] Dickstein, D.L., et al., Role of vascular risk factors and vascular dysfunction in Alzheimer’s disease. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine: A Journal of Translational and Personalized Medicine, 2010. 77(1): p. 82-102.
[24] Tiemeier, H., Biological risk factors for late life depression. European journal of epidemiology, 2003. 18(8): p. 745-750.
[25] Pesonen, E., et al., High dose methylprednisolone and endothelial glycocalyx in paediatric heart surgery. Acta Anaesthesiologica Scandinavica, 2016. 60(10): p. 1386- 1394.